Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
IPO Year: 1997
Exchange: NASDAQ
Website: cerus.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/12/2024 | $5.00 | Buy | Craig Hallum |
1/20/2023 | Buy → Neutral | BTIG Research | |
1/17/2023 | $3.75 | Overweight → Equal-Weight | Stephens |
Craig Hallum initiated coverage of Cerus with a rating of Buy and set a new price target of $5.00
BTIG Research downgraded Cerus from Buy to Neutral
Stephens downgraded Cerus from Overweight to Equal-Weight and set a new price target of $3.75
First Half of 2024 Product Revenue Increased 20% from Prior Year Period Increasing Full-Year 2024 Product Revenue Guidance Range from $172-175 Million to $175-178 Million Cerus Corporation (NASDAQ:CERS) today announced financial results for its second quarter and six months ended June 30, 2024. Total revenue for the three and six months ended June 30, 2024 was comprised of (in thousands, except %): Three Months Ended Six Months Ended June 30, Change June 30, Change 2024 2023 $ % 2024 2023 $ % Product Revenue $ 45,079 $ 38,853 $
Cerus Corporation (NASDAQ:CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A rep
Cerus Corporation (NASDAQ:CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier this year. "We are very pleased to welcome Mr. Gregory to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Mr. Gregory brings a wealth of experience and expertise across the global transfusion medicine market, h
Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs Cerus Corporation (NASDAQ:CERS) today announced a lunch symposium and selection of abstracts at the 38th International Congress of the International Society of Blood Transfusion (ISBT), taking place in Barcelona, Spain, from June 23 through June 27. Transfusion medicine experts and professionals from around the world attend the ISBT Congress. The following is a list of selected presentations and abstracts of interest for Cerus. All presentation times are listed in Central European Summer Time (CEST). The full
Cerus Corporation (NASDAQ:CERS) is proud to announce its celebration of World Blood Donor Day 2024. In 2005, the World Health Assembly designated June 14 as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. For 2024, the focus of this day is on all blood donors, essential for ensuring patients have access to blood transfusion, as well as on efforts to overcome challenges and make progress to universally accessible safe blood transfusion. The 2024 slogan for World Blood Donor Day is "20 years of celebrating giving: thank you blood donors!" "Blood donors are the foundation of the global blood supply, a
Cerus Corporation (NASDAQ:CERS) announced today that Kevin Green, Cerus' chief financial officer, is scheduled to participate at the 21st Annual Craig-Hallum Institution Investor Conference in Minneapolis, on Wednesday, May 29th. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathog
First Quarter Product Revenue Increased 24% from Prior Year Quarter Cerus Corporation (NASDAQ:CERS) today announced financial results for the first quarter ended March 31, 2024. Recent highlights include: First-quarter 2024 total revenue was comprised of (in thousands, except %): Three Months Ended March 31, Change 2024 2023 $ % Product Revenue $ 38,365 $ 30,974 $ 7,391 24% Government Contract Revenue 5,030 7,502 (2,472 ) -33% Total Revenue $ 43,395 $
Cerus Corporation (NASDAQ:CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay
Cerus Corporation (NASDAQ:CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year. All INTERCEPT Platelet Processing Sets in both customer and Cerus inventories are now eligible for this six-month extension. This shelf-life extension applies to all sizes of INTERCEPT Platelet Processing Sets currently available in the U.S. "We are pleased with this successful and timely outcome to our reg
Trial met the primary efficacy endpoint demonstrating non-inferiority of the incidence of acute kidney injury for INTERCEPT Red Blood Cells compared to conventional red blood cells Cerus Corporation (NASDAQ:CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients. The trial met its primary efficacy endpoint, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs as measured by the incidence of acute kidney injury (AKI) following transfusion of study RBCs. AKI is a sensitive transfusion efficacy indicator of RBC tissue oxyg
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
S-8 - CERUS CORP (0001020214) (Filer)
10-Q - CERUS CORP (0001020214) (Filer)
8-K - CERUS CORP (0001020214) (Filer)
8-K - CERUS CORP (0001020214) (Filer)
8-K - CERUS CORP (0001020214) (Filer)
SD - CERUS CORP (0001020214) (Filer)
10-Q - CERUS CORP (0001020214) (Filer)
8-K - CERUS CORP (0001020214) (Filer)
DEFA14A - CERUS CORP (0001020214) (Filer)
DEF 14A - CERUS CORP (0001020214) (Filer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
3 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
SC 13G/A - CERUS CORP (0001020214) (Subject)
SC 13G/A - CERUS CORP (0001020214) (Subject)
SC 13G/A - CERUS CORP (0001020214) (Subject)
SC 13G/A - CERUS CORP (0001020214) (Subject)
SC 13G/A - CERUS CORP (0001020214) (Subject)
SC 13G/A - CERUS CORP (0001020214) (Subject)
SC 13G/A - CERUS CORP (0001020214) (Subject)
SC 13G/A - CERUS CORP (0001020214) (Subject)
SC 13G/A - CERUS CORP (0001020214) (Subject)
SC 13G/A - CERUS CORP (0001020214) (Subject)
Cerus Corporation (NASDAQ:CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier this year. "We are very pleased to welcome Mr. Gregory to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Mr. Gregory brings a wealth of experience and expertise across the global transfusion medicine market, h
Cerus Corporation (NASDAQ:CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the Company's Executive Leadership Team. "We are excited to welcome Alicia to the Cerus team," said William "Obi" Greenman, Cerus' president and chief executive officer. "As we advance on key global commercial and pipeline initiatives, our talent, leadership and organization structure across all levels of the organization w
Cerus Corporation (NASDAQ:CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors. "We are pleased to welcome Dr. Shan to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Dr. Shan is an accomplished, leading voice in the transfusion community, with more than twenty-five years of experience in the field, bringing a wealth of knowledge and insight to our Board. In addition, Dr. Shan has extensive experience with international blood bank practices including the Chinese transfusion market. We expect to benefit from Dr. Shan's expertise as we co
Cerus Corporation (NASDAQ:CERS) today announced the appointment of Ann Lucena, CEO of San Ramon Regional Medical Center (SRRMC), to its Board of Directors. SRRMC, a 123-bed acute care hospital located in the East Bay Area, is part of a joint venture involving Tenet Healthcare. She also serves as the chairperson of the board overseeing the joint venture between John Muir Health and San Ramon Regional Medical Center. "We are delighted to welcome Ann to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Ann is an accomplished healthcare executive who has built an impressive track record managing San Ramon Regional Medical Center over the last several years. Her addition to
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 300 points on Wednesday. Shares of ASML Holding N.V. (NASDAQ:ASML) fell in today's pre-market trading following the release of second-quarter results. The Dutch company reported a second-quarter net income of 1.6 billion euros ($1.75 billion) on revenues of 6.2 billion euros ($6.77 billion), surpassing analysts' expectations of 1.41 billion euros on revenue of 6.04 billion euros, Reuters reported on Wednesday. The new bookings for the quarter stood at 5.6 billion euros ($6.11 billion), a significant increase from the 3.6 billion euros in the first quarter of 2024. ASML shares dipped 6.8% to $995.90 i
Shares of Bloom Energy Corporation (NYSE:BE) rose sharply in today's pre-market trading after the company announced a strategic partnership with CoreWeave. Bloom Energy said it entered into a partnership to deploy its proprietary fuel cells to generate on-site power for CoreWeave at a high-performance data center in Illinois. Bloom Energy shares jumped 12.1% to $16.90 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Shimmick Corporation (NASDAQ:SHIM) gained 53% to $3.09 in pre-market trading after the company received a $27.6 million subcontract for the Sunol Valley Water Treatment Plant Ozonation Project. Aptevo Therapeutics Inc. (NA
The Dow Jones index closed lower by over 80 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Earth Science Tech The Trade: Earth Science Tech, Inc. (OTC:ETST) Director Yovan Arturo Sanchez bought a total of 10,500 shares at an average price of $0.10. To acquire these shares, it cost around $1,050. What's Happening: On Jan. 29, Earth Scien
The Dow Jones index closed higher by over 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. ESS Tech The Trade: ESS Tech, Inc. (NYSE:GWH) Director Harry Quarls bought a total of 42,690 shares at an average price of $0.84. To acquire these shares, it cost around $35,817. What's Happening: On May 7, ESS Tech posted a narrower-than-expe
Cantor Fitzgerald analyst Ross Osborn maintains Cerus (NASDAQ:CERS) with a Overweight and raises the price target from $3 to $4.
Craig-Hallum initiates coverage on Cerus (NASDAQ:CERS) with a Buy rating and announces Price Target of $5.
U.S. stock futures were mixed this morning, with the Dow futures falling by around 10 points on Monday. Shares of Perion Network Ltd. (NASDAQ:PERI) fell sharply in today’s pre-market trading after the company slashed FY24 revenue guidance. Perion Network said it sees first-quarter revenue of $157 million, versus market estimates of $175.53 million. The company said it now expects FY24 revenue of $590 million to $610 million, versus prior outlook of $860 million to $880 million. Perion Network shares dipped 37.6% to $13.17 in pre-market trading. Here are some big stocks recording losses in today’s pre-market trading session. BRC Inc. (NYSE:BRCC) shares fell 7.8% to $4.38 in pre-marke
Gainers Longeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by 11.96% to $1.31. The market value of their outstanding shares is at $2.1 million. Etao International Co (NASDAQ:ETAO) stock moved upwards by 11.11% to $2.7. The market value of their outstanding shares is at $13.8 million. 180 Life Sciences (NASDAQ:ATNF) shares rose 7.35% to $2.39. The market value of their outstanding shares is at $1.7 million. Inovio Pharmaceuticals (NASDAQ:INO) stock rose 6.99% to $12.62. The market value of their outstanding shares is at $294.9 million. Gossamer Bio
Cerus Corporation (NASDAQ:CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year. All INTERCEPT Platelet Processing Sets in both customer and Cerus inventories are now eligible for this six-month extension. This shelf-life extension applies to all sizes of INTERCEPT Platelet Processing Sets currently available in the U.S."We are pleased with this successful and timely outcome to our regulat
On Wednesday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Block Inc (NYSE:SQ) amidst Bitcoin (CRYPTO: BTC) prices recovering. The Block Inc Trade The sale, worth $3.5 million, was executed through Ark's flagship ARK Innovation ETF (NYSE:ARKK) and ARK Next Generation Internet ETF (NYSE:ARKW) with a total of 42,608 shares sold. The value of the trade, calculated from the latest closing price of $81.46. Notably, at the time of writing, Bitcoin traded nearly 6.6% higher at $67,330.71. Ark has sold Block shares in every trading session of the current week. On Monday, Ark sold Block shares worth $8.95 million and on Tuesday, the firm sold $7.5 million worth.
First Half of 2024 Product Revenue Increased 20% from Prior Year Period Increasing Full-Year 2024 Product Revenue Guidance Range from $172-175 Million to $175-178 Million Cerus Corporation (NASDAQ:CERS) today announced financial results for its second quarter and six months ended June 30, 2024. Total revenue for the three and six months ended June 30, 2024 was comprised of (in thousands, except %): Three Months Ended Six Months Ended June 30, Change June 30, Change 2024 2023 $ % 2024 2023 $ % Product Revenue $ 45,079 $ 38,853 $
Cerus Corporation (NASDAQ:CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A rep
First Quarter Product Revenue Increased 24% from Prior Year Quarter Cerus Corporation (NASDAQ:CERS) today announced financial results for the first quarter ended March 31, 2024. Recent highlights include: First-quarter 2024 total revenue was comprised of (in thousands, except %): Three Months Ended March 31, Change 2024 2023 $ % Product Revenue $ 38,365 $ 30,974 $ 7,391 24% Government Contract Revenue 5,030 7,502 (2,472 ) -33% Total Revenue $ 43,395 $
Cerus Corporation (NASDAQ:CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay
Sequential Revenue Growth in the Fourth Quarter Driven by Sales in North America Narrowed GAAP Net Loss Attributable to Cerus Corporation to $1.3 Million for the Fourth Quarter and Achieved Goal of Adjusted EBITDA Breakeven for the Fourth Quarter Reiterating Full-Year 2024 Product Revenue Guidance Range of $172-175 Million Cerus Corporation (NASDAQ:CERS) today announced financial results for the fourth quarter and full year ended December 31, 2023. Recent highlights include: Fourth-quarter 2023 and full-year 2023 total revenue was comprised of (in thousands, except %): Three Months Ended Twelve Months Ended
Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the ev
Cerus Corporation (NASDAQ:CERS) today announced financial results for the third quarter ended September 30, 2023. Recent highlights include: Third quarter 2023 total revenue of $47.3 million was comprised of total product revenue of $39.8 million and government contract revenue of $7.5 million. Completed Phase 3 ReCePI study enrollment in cardiovascular surgery patients, with top-line data readout on track for Q1 2024. Attended first in-person AABB Annual Meeting since 2019, where presentations from transfusion medicine leaders highlighted the growing experience with the benefits of INTERCEPT-treated products, including INTERCEPT platelets and INTERCEPT Fibrinogen Complex (IFC).
Cerus Corporation (NASDAQ:CERS) announced today that its third quarter 2023 financial results will be released on Thursday, November 2, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A re
Cerus Corporation (NASDAQ:CERS) today announced financial results for the second quarter ended June 30, 2023. Recent highlights include: Second quarter 2023 total revenue of $47.7 million was comprised of total product revenue of $38.9 million and government contract revenue of $8.9 million. Received positive feedback for INTERCEPT Red Blood Cells CE Mark submission in clarification meeting with EU competent authority, the Dutch Medicines Evaluation Board (CBG), supporting possible CE Mark approval decision under the EU Medical Device Regulation (MDR) in the second half of 2024. Planned completion of Phase 3 ReCePI study enrollment in cardiovascular surgery patients this year, wi
Cerus Corporation (NASDAQ:CERS) announced today that its second quarter 2023 financial results will be released on Wednesday, August 2, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A re